Articles from Viz.ai, Inc.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, “Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,” highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) time, expediting treatment and improving patient outcomes.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz 3D CTA, a new solution that automatically converts computed tomography angiography (CTA) scans into high-resolution, AI-enhanced 3D images for faster and clearer neurovascular visualization. Fully integrated into the Viz.ai platform, this capability enables care teams to interact with complex neurovascular anatomy in real-time — automatically removing bone and venous structures to enhance clarity and support time savings in stroke and aneurysm workflows.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data from the study PFO-ACCESS: Augmenting Communications for Medical Care or Closure in the Evaluation of Stroke Patients With Cardiac Shunts demonstrating the impact of the Viz Connect® module in improving cryptogenic stroke patient management. The study results were presented by Yasaman Pirahanchi, MD, Vascular Neurology Fellow at UC San Diego, during the 2025 International Stroke Conference in Los Angeles, CA, and simultaneously published in Stroke: Vascular and Interventional Neurology.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an expanded partnership with Softek Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases. This partnership will enable healthcare providers to make timely decisions for patients with cerebral aneurysms while ensuring patients are not lost to follow-up.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced expanded lung disease software capabilities. New natural language processing (NLP) capabilities, on top of imaging AI, will extend Viz.ai’s pulmonary solutions by mining clinical insights from the electronic health record (EHR) and identifying and managing patients with lung disease. The software will be incorporated into Viz.ai’s innovative platform to accelerate and enhance the care process, reducing time to treatment and potentially improving outcomes for these patients.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of Viz LVO in the management and outcomes of patients with large vessel occlusions (LVO), a type of ischemic stroke that occurs when a major artery in the brain is blocked. Viz LVO, part of the Viz Neuro suite of artificial intelligence (AI)-powered solutions, automatically detects and triages suspected LVO patients and has been shown to reduce delays in acute stroke treatment.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, is pleased to announce that its CEO and co-founder, Dr. Chris Mansi, has been named an Innovator on the prestigious 2024 TIME100 AI list, an honor that recognizes the world’s 100 most influential people advancing and shaping artificial intelligence (AI).

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with the Hypertrophic Cardiomyopathy Association (HCMA), the preeminent organization improving the lives of those with hypertrophic cardiomyopathy (HCM), to support, educate and advance research for HCM.

Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams. For stroke patients who are at risk of atrial fibrillation (“AF”) post-stroke and may need additional cardiac monitoring, stroke care teams in the U.S. will have the opportunity to use the Viz Connect™ solution, a software tool that automates the communication across disciplines, including neurology and cardiology.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the expansion into outpatient ambulatory centers to accelerate clinical trial recruitment. Amavita Heart and Vascular Health™, with facilities spanning four locations in Miami-Dade County, has taken a pioneering step by integrating Viz.ai technology into their outpatient ambulatory centers to screen and recruit patients in a clinical study on heart failure, sponsored by a leading, global biopharma company.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection. Two studies have demonstrated the real-world clinical efficacy of Viz.ai's PE Module to quickly and accurately identify PE and associated right heart strain, accelerate care coordination, and improve healthcare workflow efficiency. Pulmonary embolism is a severe medical condition, which affects around 900,000 people in the U.S. every year, and often challenging to diagnose and treat due to overlapping symptoms with other diseases.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, M.D., CEO and Co-Founder, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023 at 7:30am ET in New York, NY.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has been named a Best Place to Work by Comparably two years in a row. The Company received two Comparably Best Place to Work Awards for Best Company Outlook and Best Leadership Teams in 2023.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has been named to the 2023 Forbes AI 50 list of the most promising private artificial intelligence (AI) startups globally. This is the 4th time Viz.ai has been recognized in the Forbes AI 50 list.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced at TraumaCon 2023 the introduction of Viz Trauma Suite, a software solution designed to support trauma care providers as they prepare to meet new requirements in the American College of Surgeons (ACS) trauma center standards. Viz.ai’s high-fidelity mobile viewer and communication platform will help to reduce team response times for trauma patients, enabling faster care and addressing resource constraints.

Fourth paragraph, first sentence of release should read: Viz AAA uses artificial intelligence to automatically search for the presence of an abdominal aortic aneurysm from computed tomography angiography (CTA) from any scanner in a hospital network (instead of Viz AAA uses artificial intelligence to automatically search for the presence of an abdominal aortic aneurysm from any computed tomography angiography (CTA) scan of the chest from any scanner in a hospital network.).

Viz.ai, the leader in AI-powered disease detection and care coordination, today announced it will use its VizTM RECRUIT platform to optimize patient enrollment for the NIH-funded1 Pulmonary Embolism—Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial. The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.

Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software (VizTM HCM) intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. Viz.ai has submitted a de novo request to the U.S. Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.

Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a collaboration with BIOS Clinical Trials Coordinating Center (BIOS CTTC) at Johns Hopkins University, to expedite patient enrollment for the National Institutes of Health (NIH) funded Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) study1.

Viz.ai, the leader in AI-powered disease detection and care coordination, and TeleSpecialists LLC, a physician-owned management service organization committed to providing exceptional emergent and non-emergent neurology and psychiatric patient care via telemedicine, announced new data presented today at the International Stroke Conference (ISC) from the VALIDATE (Validation of Artificial intelligence to LImit Delays in Acute stroke Treatment and Endovascular therapy) study. The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Cercare Medical, which delivers next-level medical imaging with CT and MRI. The partnership will incorporate Cercare Perfusion, a fully-automated, simple-to-use, patient-specific perfusion software, into the Viz.ai platform.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic partnership with Vastrax, the leading full-service, vascular clinical research organization (CRO). Together, Viz.ai and Vastrax will accelerate clinical trial enrollment for research on novel neurovascular therapies.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases. This partnership will enable healthcare providers to make timely, critical decisions for aortic aneurysm patients while improving compliance with pre- and post-surgical surveillance programs.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today shared highlights of new data being presented at the Society of Vascular and Interventional Neuroradiology (SVIN) in Los Angeles next week, demonstrating the significant impact of Viz ANEURYSM at a large hospital system.

AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS-- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a full cardiology suite to speed and improve patient access to innovative cardiovascular treatments. Announced during the American Heart Association (AHA) Scientific Sessions, Viz Cardio Suite leverages AI-powered disease detection, workflow optimization, and care team coordination to provide efficiencies in the delivery of cardiovascular care.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has partnered with Us2.ai, the developer of AI software that fully automates a complete echocardiography, or heart ultrasound, report. Under the partnership, Viz.ai will offer Us2.ai’s FDA-cleared and CE Marked echocardiogram viewing and measurement tools with the Viz™ Platform to improve and speed the coordination of care for patients with suspected heart disease, the leading cause of death worldwide.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO). Choe will report to CEO Chris Mansi, overseeing global marketing strategy, brand and communications, product marketing and demand generation.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless new component of the Viz PE Solution. The algorithm is designed to quickly and accurately measure the diameter of the ventricles of the heart to provide the ratio of the maximum right ventricle (RV) diameter versus that of the left ventricle (LV). Automating this key patient risk indicator will enable care teams to respond more quickly than before.

Viz.ai, the leading AI-powered disease detection and intelligent care coordination platform, announced today it is partnering with Hyperfine, Inc. (Nasdaq: HYPR), creator of the first FDA-cleared point-of-care magnetic resonance imaging (MRI) device, Swoop®. Together, they will bring MRI to the patient’s bedside and deliver valuable insights to the clinician’s fingertips for timely decision making.

Viz.ai, the world leader in artificial intelligence (AI) powered care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM. The new algorithm uses AI to detect suspected cerebral aneurysms, enabling hospital systems to ensure that once detected, patients are captured and the aneurysm workflow across an entire health system is standardized. This ensures that patients receive the appropriate follow-up care and creates significant financial benefits for hospital systems and payers. Viz ANEURYSM will serve as a first of its kind population health tool to facilitate population screening and enhanced care management.

Data from several new studies presented this week at the American Heart Association International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ai’s intelligent care coordination platform for stroke in real world settings across multiple commercial modules. Three posters and one abstract presented at the meeting from three institutions conclude there is a positive impact to workflow and patient care from the use of multiple Viz Platform modules, including Viz LVO (for large vessel occlusion) and Viz ICH (for intracranial hemorrhage).

Viz.ai and TeleSpecialists, LLC have entered a strategic partnership that will bring AI-powered stroke care together with leading telestroke neurologists to optimize time to treatment and improve patient outcomes across the United States. The partnership combines the Viz Intelligent Care Coordination platform and the expertise of TeleSpecialists’ neurologists to help advance medicine by alerting providers and giving them direct access to high fidelity imaging, patient information, and HIPAA-compliant communication. This partnership will further facilitate stroke care coordination even when the patient and provider are hundreds of miles apart. Moving forward, the two organizations will partner on additional technology, workflows, and research opportunities.

Today at the Society of Vascular and Interventional Neurology (SVIN) 2021 Annual Meeting in Phoenix, Viz.ai, the world leader in AI-powered intelligent care coordination, introduced Viz ANX, the first and only AI-powered suspected cerebral aneurysm detection and care coordination platform. Viz ANX is designed to help ensure every patient who presents with a cerebral aneurysm is quickly identified and receives the correct follow-up, helping prevent a devastating rupture or hemorrhage. The company also introduced Viz SDH, a research-only algorithm supporting the EMBOLISE trial that detects suspected subdural hematoma (SDH) to alert clinicians to potentially eligible study candidates.

Viz.ai - the world leader in AI-driven intelligent care coordination, today announced the U.S. commercial launch of its AI-powered modules for pulmonary embolism and aortic disease. Debuting at the 48th annual VEITHsymposium November 16 – 20 in Orlando, Fla., the new modules allow for faster clinical decision making and improved care coordination for patients suffering from these two life-threatening conditions.

Viz.ai, the world leader in AI-powered intelligent care coordination, has been named to the Forbes 2021 Next Billion-Dollar Startups list. The prestigious list includes the 25 fastest-growing venture-backed startups in 2021 and follows the company’s inclusion in the Forbes AI 50 list for the third consecutive year. Viz.ai was also named in the prestigious State of AI report that highlights companies showing real-world performance breakthroughs in computer vision and biology over the past 12 months.

Viz.ai, the world leader in AI-driven intelligent care coordination, has received a New Technology Add-on Payment (NTAP) renewal from Centers for Medicare & Medicaid Services (CMS) for its AI-powered stroke triage module, Viz LVO (formerly known as Viz ContaCT). The reimbursement opportunity will continue to give more patients access to life-changing stroke technology, which has demonstrated significant improvements to patient outcomes through FY 2022. Viz LVO is eligible for reimbursement up to $1,040 per eligible patient.